[go: up one dir, main page]

WO2001075029A3 - Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide - Google Patents

Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide Download PDF

Info

Publication number
WO2001075029A3
WO2001075029A3 PCT/CN2001/000386 CN0100386W WO0175029A3 WO 2001075029 A3 WO2001075029 A3 WO 2001075029A3 CN 0100386 W CN0100386 W CN 0100386W WO 0175029 A3 WO0175029 A3 WO 0175029A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide encoding
human factor
discloses
associated human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/000386
Other languages
English (en)
Chinese (zh)
Other versions
WO2001075029A2 (fr
Inventor
Yumin Mao
Yi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to AU56059/01A priority Critical patent/AU5605901A/en
Publication of WO2001075029A2 publication Critical patent/WO2001075029A2/fr
Publication of WO2001075029A3 publication Critical patent/WO2001075029A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un nouveau polypeptide, un facteur humain 11 associé à NF-E2, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment de toutes sortes de tumeurs, des troubles du développement de l'embryon, des troubles du développement et de la croissance, des inflammations, des maladies immunitaires, de l'hémopathie et de l'infection par VIH. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour le facteur humain 11 associé à NF-E2.
PCT/CN2001/000386 2000-03-24 2001-03-23 Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide Ceased WO2001075029A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56059/01A AU5605901A (en) 2000-03-24 2001-03-23 A novel polypeptide, nf-e2-associated human factor 11 and the polynucleotide encoding the polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN 00115100 CN1315351A (zh) 2000-03-24 2000-03-24 一种新的多肽——人一种组织或发育阶段特异转录因子相关因子11和编码这种多肽的多核苷酸
CN00115100.2 2000-03-24

Publications (2)

Publication Number Publication Date
WO2001075029A2 WO2001075029A2 (fr) 2001-10-11
WO2001075029A3 true WO2001075029A3 (fr) 2002-05-10

Family

ID=4584569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000386 Ceased WO2001075029A2 (fr) 2000-03-24 2001-03-23 Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide

Country Status (3)

Country Link
CN (1) CN1315351A (fr)
AU (1) AU5605901A (fr)
WO (1) WO2001075029A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990090A (en) * 1993-09-20 1999-11-23 The University Of Michigan Methods and compositions for treatment of diseases
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子NFκB活性化阻害剤
CN1243444A (zh) * 1997-01-15 2000-02-02 凤凰药理学公司 被修饰的肿瘤坏死因子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990090A (en) * 1993-09-20 1999-11-23 The University Of Michigan Methods and compositions for treatment of diseases
CN1243444A (zh) * 1997-01-15 2000-02-02 凤凰药理学公司 被修饰的肿瘤坏死因子
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子NFκB活性化阻害剤

Also Published As

Publication number Publication date
AU5605901A (en) 2001-10-15
CN1315351A (zh) 2001-10-03
WO2001075029A2 (fr) 2001-10-11

Similar Documents

Publication Publication Date Title
WO2001083688A3 (fr) Nouveau polypeptide, sous-unite humaine 13 phosphatidylinositol-4-phosphate-5-kinase ii beta, et polynucleotide codant pour ce polypeptide
WO2001075029A3 (fr) Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2001075036A3 (fr) Nouveau polypeptide, immunophiline humaine 14, et polynucleotide codant pour ce polypeptide
WO2001075016A3 (fr) Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide
WO2001075053A3 (fr) Nouveau polypeptide, chaperonine humaine 14, et polynucleotide codant pour ce polypeptide
WO2001075058A3 (fr) Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide
WO2001075062A3 (fr) Nouveau polypeptide, hydrogenase humaine 10, et polynucleotide codant pour ce polypeptide
WO2001075054A3 (fr) Nouveau polypeptide, facteur humain de regulation 30 de la transcription de la microglobuline, et polynucleotide codant pour ce polypeptide
WO2001083681A3 (fr) Nouveau polypeptide, dihydroorotase humaine 21, et polynucleotide codant pour ce polypeptide
WO2001075011A3 (fr) Nouveau polypeptide, proteine humaine de constitution 10 de cytochromes, et polynucleotide codant pour ce polypeptide
WO2001075023A3 (fr) Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase humaine 9, et polynucleotide codant pour ce polypeptide
WO2001075025A3 (fr) Nouveau polypeptide, thyroglobuline humaine 9, et polynucleotide codant pour ce polypeptide
WO2001075048A3 (fr) Nouveau polypeptide, proteine ribosomale humaine s11 23, et polynucleotide codant pour ce polypeptide
WO2001075056A3 (fr) Nouveau polypeptide, clathrine humaine a chaine legere 20, et polynucleotide codant pour ce polypeptide
WO2001079431A3 (fr) Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide
WO2001077287A3 (fr) Nouveau polypeptide, globine humaine de l'uterus 11, et polynucleotide codant pour ce polypeptide
WO2001075024A3 (fr) Nouveau polypeptide, facteur humain 13 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2001094534A3 (fr) Nouveau polypeptide, facteur humain de transcription 9.57, et polynucleotide codant ce polypeptide
WO2001075035A3 (fr) Nouveau polypeptide, peroxydase proteine humaine 9, et polynucleotide codant pour ce polypeptide
WO2001075034A3 (fr) Nouveau polypeptide, peroxydase proteine humaine 15, et polynucleotide codant pour ce polypeptide
WO2001075015A3 (fr) Nouveau polypeptide, fat24, et polynucleotide codant pour ce polypeptide
WO2001083685A3 (fr) Nouveau polypeptide, proteine cap 10, et polynucleotide codant pour ce polypeptide
WO2001075018A3 (fr) Nouveau polypeptide, facteur humain de regulation de la transcription 31, et polynucleotide codant pour ce polypeptide
WO2001075046A3 (fr) Nouveau polypeptide, gene humain de regulation 17 du cycle mitotique, et polynucleotide codant pour ce polypeptide
WO2001083682A3 (fr) Nouveau polypeptide, proteine pax humaine 11.6, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP